Purchase Order 75N93022P01145

<p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Genscript USA Inc. for sequencing and gene synthesis services for 100 samples on March 17, 2022, with a ceiling value of $15,389.60. Work is performed in Piscataway, New Jersey. The order is firm fixed price with no set-aside designation and an ultimate completion date of March 16, 2023.</p>

<p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Genscript USA Inc. for $17,209.00 on September 18, 2023, for custom gene synthesis and expression services. Performance occurs in Bethesda, Maryland. The order is firm fixed price with no small business set-aside. The ultimate completion date is December 31, 2023.</p>

The Department of Health and Human Services' National Institutes of Health's National Institute of Allergy and Infectious Diseases awarded a $11,453 purchase order to Genscript USA Inc. to provide custom peptide synthesis services in support of H1/HA programs. The firm fixed price contract runs from September 18, 2023 through December 29, 2023 and will be performed in Piscataway, New Jersey. Genscript will synthesize peptides to advance NIH's research on influenza viruses under the contract....

<p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Genscript USA Inc. valued at $14,979.75 on August 29, 2024, for monoclonal antibodies and plasmids services. The order is firm fixed price with no small business set-aside. Performance occurs in Piscataway, New Jersey. The modification de-obligates excess funds, with ultimate completion scheduled for May 18, 2026.</p>

The National Institute of Allergy and Infectious Diseases awarded a purchase order to Genscript USA Inc. on August 23, 2023, for DNA services valued at $34,502.16. The order covers gene synthesis, VectorArk cloning, and express plasmid preparation. Performance occurs in Piscataway, New Jersey. The services support development of peptide and protein immunogens and DNA constructs for MPER-scaffolded proteins used in vaccine research against HIV, influenza, Ebola, Marburg, and other infectious...

<p>Genscript USA Inc. has been awarded a $11,395.74 firm fixed price purchase order by the National Institutes of Health's National Institute of Allergy and Infectious Diseases to provide purified peptide services. The one-year contract, which runs from July 2023 through July 2024, will support NIH/NIAID's research efforts. No subcontractors or set aside designations were identified. Genscript will perform the peptide purification work at its facility in Piscataway, New Jersey.</p>

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $156,442.59 firm fixed-price purchase order to Genscript USA Inc. for gene synthesis and protein production services under the FY26 UDO Initiative (AMBIS #2136137). The contract was awarded on August 31, 2022, with an ultimate completion date of September 1, 2023, and represents work to be performed at Genscript's facility in Piscataway, New Jersey. This contract was not designated as a set-aside award and resulted...

<p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Genscript USA Inc. for $70,622.20 on August 5, 2020, for customized RAB expression synthesis under the FY26 UDO Initiative. Work is performed in Piscataway, New Jersey. The order is firm fixed price with no small business set-aside. The ultimate completion date is September 28, 2020. The requirement originated from a pre-solicitation opportunity posted July 24, 2020, with an August 3, 2020 deadline.</p>

The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases has awarded a $20,827.75 purchase order to Genscript USA Inc. to provide customized protein production using a baculovirus expression system. Performance will take place in Piscataway, New Jersey over a period of approximately three months concluding in mid-December 2023. The firm fixed price contract calls for Genscript to deliver the requested proteins without further...

The National Institute of Allergy and Infectious Diseases awarded a $16,974.27 firm fixed price purchase order to Genscript USA Inc. for antibody gene synthesis and production services. The contract was awarded on August 26, 2020, with an ultimate completion date of February 6, 2021, and was performed at Genscript's facility in Piscataway, New Jersey. This award did not utilize any set-aside designation and represents a straightforward procurement of specialized molecular biology services...